STOCK TITAN

Longeveron (LGVN) counsel reports RSU tax withholding in Form 4 filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Longeveron Inc. officer reports routine tax withholding transaction. General Counsel and Secretary Paul T. Lehr filed a Form 4 for a transaction on 01/02/2026 involving Class A Common Stock of Longeveron Inc. (LGVN).

The filing shows that 6,952 shares were withheld at a price of $0.593 per share to satisfy tax obligations tied to the vesting of a restricted stock unit (RSU) award. Following this tax withholding, Lehr beneficially owned 344,177 shares, which include RSUs that are subject to future vesting. This reflects an administrative equity compensation event rather than an open-market purchase or sale.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lehr Paul T

(Last) (First) (Middle)
1951 NW 7TH AVENUE
SUITE 520

(Street)
MIAMI FL 33136

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Longeveron Inc. [ LGVN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
General Counsel, Secretary
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 01/02/2026 F 6,952(1) D $0.593 344,177(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares withheld to satisfy tax obligations in connection with the vesting of a restricted stock unit (RSU) award.
2. Includes RSUs subject to future vesting.
Remarks:
/s/ Paul T. Lehr 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Longeveron (LGVN) report for Paul T. Lehr?

The Form 4 reports that Paul T. Lehr, General Counsel and Secretary of Longeveron Inc., had 6,952 shares of Class A Common Stock withheld on 01/02/2026 in connection with an RSU vesting.

What was the price for the shares withheld in the Longeveron (LGVN) Form 4?

The 6,952 shares of Class A Common Stock were withheld at a price of $0.593 per share to satisfy tax obligations related to an RSU award.

How many Longeveron (LGVN) shares does Paul T. Lehr own after this transaction?

After the reported transaction, Paul T. Lehr beneficially owned 344,177 shares of Longeveron Inc. Class A Common Stock, including RSUs subject to future vesting.

Was the Longeveron (LGVN) Form 4 transaction an open-market sale?

No. The footnote explains that the 6,952 shares were withheld to satisfy tax obligations related to the vesting of a restricted stock unit (RSU) award, rather than sold in the open market.

What role does the reporting person in this Longeveron (LGVN) Form 4 hold?

The reporting person, Paul T. Lehr, serves as General Counsel and Secretary of Longeveron Inc.

What do the footnotes in the Longeveron (LGVN) Form 4 explain?

One footnote states the shares were withheld to satisfy tax obligations from RSU vesting, and another notes that the reported holdings include RSUs subject to future vesting.

Longeveron Inc

NASDAQ:LGVN

LGVN Rankings

LGVN Latest News

LGVN Latest SEC Filings

LGVN Stock Data

11.33M
16.90M
14.83%
6.96%
5.26%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIAMI